Methods for treating pancreatic cancer using combination therapies
US-9717724-B2 · Aug 1, 2017 · US
Methods For Treating Pancreatic Cancer Using Combination Therapies
US2023088999A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023088999-A1 |
| Application number | US-202217824421-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 25, 2022 |
| Priority date | Jun 13, 2012 |
| Publication date | Mar 23, 2023 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
First claim
Opening claim text (preview).
1 - 20 . (canceled) 21 . A method of treating patients with metastatic adenocarcinoma of the pancreas after disease progression following antineoplastic-based therapy, comprising intravenously administering an antineoplastic therapy to the patients once every two weeks, the therapy consisting of: irinotecan sucrose octasulfate salt liposome injection in an amount providing the equivalent of 70 mg/m 2 of irinotecan free base, in combination with therapeutically effective amounts of 5-fluorouracil and leucovorin. 22 . The method of claim 21 , wherein each administration of irinotecan sucrose octasulfate salt liposome injection is infused over 90 minutes, followed by intravenous administration of leucovorin over 30 minutes, followed by intravenous administration of 5-fluorouracil over 46 hours. 23 . The method of claim 21 , further comprising premedicating the human patient with an anti-emetic prior to administering the antineoplastic therapy.
Assignees
Inventors
Classifications
Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title
Antineoplastic agents · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2023088999A1 cover?
- Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
- Who is the assignee on this patent?
- Ipsen Biopharm Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4745. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Mar 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).